213 related articles for article (PubMed ID: 25134468)
1. Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.
Peters MF; Lamore SD; Guo L; Scott CW; Kolaja KL
Cardiovasc Toxicol; 2015 Apr; 15(2):127-39. PubMed ID: 25134468
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications.
Peters MF; Scott CW; Ochalski R; Dragan YP
Assay Drug Dev Technol; 2012 Dec; 10(6):525-32. PubMed ID: 22574652
[TBL] [Abstract][Full Text] [Related]
3. Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment.
Clements M; Millar V; Williams AS; Kalinka S
Toxicol Sci; 2015 Nov; 148(1):241-60. PubMed ID: 26259608
[TBL] [Abstract][Full Text] [Related]
4. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
Himmel HM
J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
[TBL] [Abstract][Full Text] [Related]
6. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
Scott CW; Zhang X; Abi-Gerges N; Lamore SD; Abassi YA; Peters MF
Toxicol Sci; 2014 Dec; 142(2):331-8. PubMed ID: 25237062
[TBL] [Abstract][Full Text] [Related]
7. Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity.
Lamore SD; Kamendi HW; Scott CW; Dragan YP; Peters MF
Toxicol Sci; 2013 Oct; 135(2):402-13. PubMed ID: 23897988
[TBL] [Abstract][Full Text] [Related]
8. Assessment of drug-induced arrhythmic risk using limit cycle and autocorrelation analysis of human iPSC-cardiomyocyte contractility.
Kirby RJ; Qi F; Phatak S; Smith LH; Malany S
Toxicol Appl Pharmacol; 2016 Aug; 305():250-258. PubMed ID: 27343406
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
10. Functional cardiotoxicity profiling and screening using the xCELLigence RTCA Cardio System.
Xi B; Wang T; Li N; Ouyang W; Zhang W; Wu J; Xu X; Wang X; Abassi YA
J Lab Autom; 2011 Dec; 16(6):415-21. PubMed ID: 22093298
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of in vitro models of stem cell-derived cardiomyocytes to screen for potential cardiotoxicity of chemicals.
Shi M; Tien NT; de Haan L; Louisse J; Rietjens IMCM; Bouwmeester H
Toxicol In Vitro; 2020 Sep; 67():104891. PubMed ID: 32446838
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
[TBL] [Abstract][Full Text] [Related]
14. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
Sirenko O; Cromwell EF; Crittenden C; Wignall JA; Wright FA; Rusyn I
Toxicol Appl Pharmacol; 2013 Dec; 273(3):500-7. PubMed ID: 24095675
[TBL] [Abstract][Full Text] [Related]
15. New easy-to-use hybrid system for extracellular potential and impedance recordings.
Doerr L; Thomas U; Guinot DR; Bot CT; Stoelzle-Feix S; Beckler M; George M; Fertig N
J Lab Autom; 2015 Apr; 20(2):175-88. PubMed ID: 25532527
[TBL] [Abstract][Full Text] [Related]
16. From the Cover: High-Throughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during Drug Discovery.
Pointon A; Pilling J; Dorval T; Wang Y; Archer C; Pollard C
Toxicol Sci; 2017 Feb; 155(2):444-457. PubMed ID: 28069985
[TBL] [Abstract][Full Text] [Related]
17. Development of a Next-Generation Biosensing Platform for Simultaneous Detection of Mechano- and Electrophysiology of the Drug-Induced Cardiomyocytes.
Oyunbaatar NE; Dai Y; Shanmugasundaram A; Lee BK; Kim ES; Lee DW
ACS Sens; 2019 Oct; 4(10):2623-2630. PubMed ID: 31535848
[TBL] [Abstract][Full Text] [Related]
18. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening.
Rana P; Anson B; Engle S; Will Y
Toxicol Sci; 2012 Nov; 130(1):117-31. PubMed ID: 22843568
[TBL] [Abstract][Full Text] [Related]
19. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment.
Abassi YA; Xi B; Li N; Ouyang W; Seiler A; Watzele M; Kettenhofen R; Bohlen H; Ehlich A; Kolossov E; Wang X; Xu X
Br J Pharmacol; 2012 Mar; 165(5):1424-41. PubMed ID: 21838757
[TBL] [Abstract][Full Text] [Related]
20. Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cell-derived cardiomyocytes.
Jonsson MK; Wang QD; Becker B
Assay Drug Dev Technol; 2011 Dec; 9(6):589-99. PubMed ID: 22085047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
